IV Bags Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 2.78 Billion |
| Market Size (2030) | USD 4.41 Billion |
| Growth Rate (2025 - 2030) | 9.62% CAGR |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
IV Bags Market Analysis by Mordor Intelligence
The IV bags market size is USD 2.78 billion in 2025 and is projected to reach USD 4.41 billion by 2030, registering a 9.62% CAGR over the period. Demand stems from chronic-disease prevalence, the regulatory push toward DEHP-free formulations, and expanding home-infusion infrastructure. Hospitals still account for the bulk of purchases, yet value-based care is re-routing intravenous therapy toward outpatient and residential settings. California’s DEHP ban has accelerated global adoption of non-PVC materials, while recent hurricane-related shortages exposed the need for supply-chain redundancy. North America retains the largest revenue pool, but Asia-Pacific delivers the fastest unit growth as governments modernize clinical capacity and medical-tourism flows rebound.
Key Report Takeaways
By material, non-PVC solutions led with 45.10% of IV bags market share in 2024, and ethylene-vinyl-acetate (EVA) variants are forecast to expand at a 10.93% CAGR through 2030.
By capacity, the 500–1,000 ml tier held 36.90% of the IV bags market size in 2024, whereas containers exceeding 1,000 ml post the quickest 11.39% CAGR to 2030
By port type, single-port bags represented 71% of 2024 revenue, while dual-port designs advance at a projected 10.1% CAGR through 2030.
By fluid type, crystalloids commanded 70.75% of the IV bags market size in 2024; colloids grow faster at an 11.63% CAGR through 2030.
By end user, hospitals retained 67.10% of IV bags market share in 2024, whereas home-care settings record an 11.16% CAGR to 2030.
Global IV Bags Market Trends and Insights
Driver Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic diseases | +1.8% | Global, with higher impact in North America & Europe | Long term (≥ 4 years) |
| Growing preference for single-use IV bags | +1.2% | Global, led by developed markets | Medium term (2-4 years) |
| Shift toward non-PVC, DEHP-free materials | +2.1% | North America & EU leading, APAC following | Medium term (2-4 years) |
| Expansion of decentralized compounding pharmacies | +0.9% | North America primarily, expanding to Europe | Medium term (2-4 years) |
| Growth of home-infusion therapy models | +1.4% | North America & Europe core, APAC emerging | Long term (≥ 4 years) |
| Rising demand in veterinary medicine | +0.7% | Global, with concentration in developed markets | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence of Chronic Diseases
An aging population and surging incidence of diabetes, cancer, and cardiovascular disorders lengthen hospital stays and intensify intravenous drug use. Medications with poor oral bio-availability often rely on continuous infusion, raising per-episode bag consumption. Oncology regimens and dialysis further amplify fluid volumes. Because value-based reimbursement centers on outcome quality rather than unit cost, clinicians prefer precise IV formulations that optimize therapeutic efficacy.
Growing Preference for Single-Use IV Bags
Post-pandemic infection-control protocols elevated disposable devices from tactical choice to strategic standard. Single-use bags eliminate sterilization labor, cut cross-contamination liability, and streamline pharmacy workflows despite higher purchase prices. Hospitals and outpatient centers now calculate total life-cycle costs, reinforcing premium, ready-to-administer solutions.
Shift Toward Non-PVC, DEHP-Free Materials
California’s Toxic-Free Medical Device Act mandates DEHP elimination in IV bags by 2030, pushing manufacturers to pivot toward EVA and polyolefin films. Early movers—B. Braun, Fresenius Kabi—invested more than USD 1 billion in compliant lines and now tout leachate-free certificates, securing hospital contracts nationwide. Beyond safety, non-PVC materials enable recycling programs that align with hospital carbon pledges.
Expansion of Decentralised Compounding Pharmacies
FDA temporary guidance during supply disruptions validated 503B outsourcing facilities that customize parenteral admixtures locally. Hospitals are internalizing these capabilities, using robotics to reduce error and labor while ensuring supply continuity when central plants falter[1]Source: Federal Register, “Temporary Policies for Compounding Certain Parenteral Drug Products,” federalregister.gov .
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Volatile prices of medical-grade polymers | -1.1% | Global, with higher impact in cost-sensitive markets | Short term (≤ 2 years) |
| Lengthy regulatory approval timelines | -0.8% | Global, particularly in highly regulated markets | Medium term (2-4 years) |
| Supply-chain concentration in polymer film extruders | -0.9% | Global, with critical impact during disruptions | Short term (≤ 2 years) |
| Environmental disposal concerns | -0.6% | EU & North America primarily, expanding globally | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Volatile Prices of Medical-Grade Polymers
PVC, EVA, and polypropylene resins track crude-oil swings. Limited supplier diversity inflates price amplitude during geopolitical shocks. Smaller manufacturers unable to hedge long-term contracts pass surcharges on, delaying tenders and tempering adoption of premium non-PVC bags.
Lengthy Regulatory Approval Timelines
Each formulation change triggers new 510(k) or MDR filings that can add 12–18 months to market entry, discouraging smaller entrants and slowing innovation cycles. Established players with dedicated regulatory teams hold a structural edge.
Segment Analysis
By Material: Non-PVC Solutions Drive Safety Transformation
Non-PVC formulations captured 45.10% of 2024 revenue and are forecast to log a 10.93% CAGR through 2030. EVA’s chemical inertness makes it ideal for oncology drugs, while polyolefins offer steam-sterilization stability for parenteral nutrition. The IV bags market size attributable to non-PVC lines is estimated at USD 2.4 billion by 2030, reflecting the shift away from plasticizer-laden PVC. California and Massachusetts have already mandated DEHP-free procurement, and donor-funded green tenders in Africa signal broader global catch-up.
PVC remains entrenched in price-sensitive segments, yet its total-cost advantage erodes once disposal levies and carbon accounting enter the calculus. Mold-replacement cycles after 2027 provide a natural pivot point at which converters are likely to reinvest in future-proof tooling compatible with EVA or PP. This material re-mix raises switching barriers and enlarges profit pools for first movers.
Note: Segment shares of all individual segments available upon report purchase
By Capacity: Large-Volume Containers Capture Surgical Demand
Bags sized 500–1,000 ml held 36.90% share in 2024 as they meet standard peri-operative hydration needs. Containers exceeding 1,000 ml are projected to clock an 11.39% CAGR, fueled by longer organ-transplant and trauma procedures requiring continuous resuscitation. The IV bags market share for large-volume formats could crest 25% by 2030, aided by Terumo’s lightweight TERUPACK Eco design that trims resin use 23%, lowering freight emissions and waste charges.
Micro-volume 0–250 ml bags service pediatrics and niche biologics. Their unit volumes outpace revenue, but emerging closed-system connectors promise margin uplift by bundling safety technology. Across all capacities, RFID tagging expedites expiry tracking and reduces pharmacy spoilage, making digital labeling an implicit tender requirement for hospital procurement teams.
By Port Type: Dual-Port Systems Enable Complex Therapies
Single-port designs accounted for 71% of 2024 shipments because of simplicity and price. Dual-port configurations, however, deliver a 10.1% CAGR, enabling simultaneous infusion of drugs and nutritional fluids without line changes. The IV bags market size for dual-port solutions is poised to top USD 1 billion by 2030. BD’s needle-free SmartSite valve supports repeated access while mitigating needlestick risk, a feature prized in oncology wards with high manipulation frequency.
Port innovation now merges with smart-pump auto-identification: RFID-enabled ports preload pump libraries, reducing wrong-drug errors by 30% in early adopter hospitals. As biologic combo-therapies gain traction, multi-manifold bags will emerge, although regulatory verification may slow scale-up beyond tertiary centers.
By Fluid Type: Crystalloids Dominate, Colloids Accelerate
Crystalloids captured 70.75% revenue in 2024 thanks to broad indications. Normal saline retains staple status, while balanced formulations such as Ringer’s lactate gain surgical favor to avoid hyperchloremic acidosis.
Colloids, especially 5% and 20% human albumin, post an 11.63% CAGR through 2030 on the back of critical-care applications and convincing survival data in decompensated cirrhosis. Grifols’ Albutein trial showed improved five-year outcomes, spurring reimbursement across 17 countries. Synthetic starches remain under safety review, shifting hospital formularies toward natural colloids. Blood and blood-product bags form a niche exempt from DEHP bans, yet innovation around pathogen-reduction extends platelet shelf-life.
Note: Segment shares of all individual segments available upon report purchase
By End User: Hospitals Lead, Home Care Transforms
Hospitals consumed 67.10% of 2024 volume, leveraging group-purchasing organizations to negotiate discounts. Nevertheless, home-care channels expand at 11.16% CAGR as insurers reimburse outpatient infusions to cut bed-day costs. The IV bags market size for home settings will be supported by subscription models bundling disposables and nurse visits.
Ambulatory surgical centers act as a mid-growth niche, requiring rapid-turnover bags that integrate with electronic medication administration records. Veterinary clinics represent an ancillary yet double-digit growth avenue, with scaled-down port gauges tailored to small-animal catheters, reinforcing diversification beyond human medicine.
Geography Analysis
North America held 42.23% of 2024 revenue, equating to USD 1.17 billion. Federal incentives promote domestic sterile-fluid output, while California’s DEHP ban cements material migration toward EVA. The IV bags market size for the United States is forecast to touch USD 2.05 billion by 2030. Recent hurricane-sparked shortages led Congress to propose tax credits for redundant manufacturing lines, making geographic diversification a procurement criterion.
Europe displays slower topline expansion yet sharper product sophistication. Germany and France already report non-PVC adoption above 60%, and the United Kingdom trialed a closed-loop polyolefin recycling scheme that cut clinical-plastic emissions 28%, with national rollout slated by 2027. MDR compliance costs escalate entry barriers, protecting incumbents endowed with regulatory bandwidth.
Asia-Pacific delivers the fastest 11.87% CAGR. China’s ongoing hospital build-out and India’s expanding surgical volumes underpin unit demand, albeit still skewed toward PVC on price grounds. Australia committed AUD 20 million (USD 13.2 million) to scale Baxter’s Western Sydney plant[2]Source: Australian Broadcasting Corporation, “Local IV Fluid Production to Increase,” abc.net.au , bolstering self-reliance and signalling broader regional industrial policy shifts. Medical-tourism hubs like Thailand upgrade to dual-port EVA systems, aligning with visiting-patient expectations for Western-grade safety.
South America and the Middle East & Africa each contribute under 12% of revenue but promise pockets of double-digit growth. Brazil’s private hospital chains are standardizing single-use protocols, while Gulf states procure large-volume parenterals for trauma centers aligned with expanding road-infrastructure.
Competitive Landscape
The IV bags market is moderately consolidated: the top five vendors command roughly 68% of 2024 revenue. Baxter, Fresenius Kabi, and B. Braun leverage multi-continent production footprints and vertically integrated film extrusion to lock in long-term tenders. Strategy emphasis is shifting from unit capacity to value-adding service ecosystems—Baxter’s Spectrum IQ pump interfaces exclusively with its own bags, driving 97% drug-library compliance within one month of rollout.
Tier-2 players such as ICU Medical and Terumo scale via alliances: the 2024 ICU Medical–Otsuka joint venture will add 25 million units of annual North American output by 2026, diffusing single-source concentration risk. Chinese manufacturers—Sichuan Kelun, CSPC—challenge incumbents on price in tender markets, accelerating commoditization in PVC but struggling to penetrate non-PVC premium tiers without Western regulatory clearances.
Innovation vectors center on material sustainability and digital integration. Suppliers are patenting bio-based polyolefins and piloting hospital take-back loops to capture resin for closed-loop recycling. Concurrently, RFID-enabled ports feed infusion data into EMRs, enabling predictive maintenance and reducing human error. Dual-chamber drug-device combinations push up approval complexity but promise higher margins and stronger clinical lock-in.
IV Bags Industry Leaders
-
Baxter international Inc.
-
Technoflex
-
ICU Medical, Inc.
-
Sippex IV bags
-
Polycine GmBH
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- March 2025: Australian government committed AUD 20 million to expand Baxter’s Western Sydney plant, lifting capacity to 80 million units by 2027
- May 2025: ICU Medical and Otsuka Pharmaceutical Factory launched a joint venture to scale IV-solution manufacturing, operations begin Q2 2025
Global IV Bags Market Report Scope
As per the scope of the report, IV bags are containers to store a liquid used for intravenous administration to patients suspended to slender poles called IV poles. IV fluids prevent dehydration, maintain blood pressure, or give patients medicines or nutrients. The IV Bags Market is segmented by material type (polyethylene, polyvinylchloride, polypropylene, and other material types), capacity (0-250 ml, 250-500 ml, 500-1000 ml), chamber type (single chamber and multi-chamber), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| PVC | |
| Non-PVC | Polyolefin (PP) |
| Ethylene Vinyl Acetate (EVA) | |
| Others |
| 0–250 ml |
| 250–500 ml |
| 500–1,000 ml |
| More than 1,000 ml |
| Crystalloids | Normal Saline (0.9 % NaCl) |
| Dextrose Solutions | |
| Ringer’s Lactate | |
| Colloids | Albumin |
| Dextran & Others | |
| Blood & Blood Products |
| Hospitals |
| Clinics |
| Home Care |
| Ambulatory Surgical Centers |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| India | |
| Japan | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| South America | Brazil |
| Argentina | |
| Rest of South America | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa |
| By Material | PVC | |
| Non-PVC | Polyolefin (PP) | |
| Ethylene Vinyl Acetate (EVA) | ||
| Others | ||
| By Capacity | 0–250 ml | |
| 250–500 ml | ||
| 500–1,000 ml | ||
| More than 1,000 ml | ||
| By Fluid Type | Crystalloids | Normal Saline (0.9 % NaCl) |
| Dextrose Solutions | ||
| Ringer’s Lactate | ||
| Colloids | Albumin | |
| Dextran & Others | ||
| Blood & Blood Products | ||
| By End User | Hospitals | |
| Clinics | ||
| Home Care | ||
| Ambulatory Surgical Centers | ||
| Others | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| India | ||
| Japan | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
What is the estimated global value of the IV bags market in 2025 and its projected revenue by 2030?
It is USD 2.78 billion in 2025 and is forecast to rise to USD 4.41 billion by 2030, reflecting a 9.62% CAGR.
Which non-PVC materials are gaining the most traction as DEHP-free alternatives?
Ethylene-vinyl-acetate (EVA) and polyolefin blends lead adoption, together holding 45.10% share in 2024 and expanding at a 10.93% CAGR through 2030.
Which geographic region currently contributes the largest revenue for IV bags?
North America accounts for 42.23% of 2024 turnover, supported by advanced healthcare infrastructure and early regulatory moves on DEHP elimination.
How quickly are home-infusion applications for IV bags expanding?
Home-care settings are logging an 11.16% CAGR to 2030 as payers reimburse at-home intravenous antibiotics, nutrition and immunoglobulin therapy.
When does Californias law require full removal of DEHP from intravenous solution containers?
The Toxic-Free Medical Device Act mandates DEHP-free IV bags no later than 1 January 2030, triggering nationwide material transitions.
Which capacity range of IV bags is recording the fastest growth?
Containers larger than 1,000 ml are advancing at an 11.39% CAGR because complex surgeries and extended critical-care protocols require longer infusions
Page last updated on:
